|
1
|
Vauthey JN and Blumgart LH: Recent
advances in the management of cholangiocarcinomas. Semin Liver Dis.
14:109–114. 1994.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lazaridis KN and Gores GJ:
Cholangiocarcinoma. Gastroenterology. 128:1655–1667.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Khan SA, Davidson BR, Goldin R, Pereira
SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC,
Thursz MR and Wasan H: British Society of Gastroenterology:
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
Consensus document. Gut ٦. (Suppl 51):VI1–9. 2002.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sandhu DS, Shire AM and Roberts LR:
Epigenetic DNA hypermethylation in cholangiocarcinoma: Potential
roles in pathogenesis, diagnosis and identification of treatment
targets. Liver Int. 28:12–27. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Limpaiboon T: Epigenetic aberrations in
cholangiocarcinoma: Potential biomarkers and promising target for
novel therapeutic strategies. Asian Pac J Cancer Prev. 13
(Suppl):S41–S45. 2012.PubMed/NCBI
|
|
7
|
Khan SA, Taylor-Robinson SD, Toledano MB,
Beck A, Elliott P and Thomas HC: Changing international trends in
mortality rates for liver, biliary and pancreatic tumours. J
Hepatol. 37:806–813. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Patel T: Worldwide trends in mortality
from biliary tract malignancies. BMC Cancer. 2(10)2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shaib YH, Davila JA, McGlynn K and
El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in
the United States: A true increase? J Hepatol. 40:472–477.
2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rosai J: Ackerman's Surgical Pathology.
Vol 2. 8th edition. Mosby. pp982–989. 1996.
|
|
11
|
Rea DJ, Heimbach JK, Rosen CB, Haddock MG,
Alberts SR, Kremers WK, Gores GJ and Nagorney DM: Liver
transplantation with neoadjuvant chemoradiation is more effective
than resection for hilar cholangiocarcinoma. Ann Surg. 242:451–458;
discussion 458-461. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Patel AH, Harnois DM, Klee GG, LaRusso NF
and Gores GJ: The utility of CA 19-9 in the diagnoses of
cholangiocarcinoma in patients without primary sclerosing
cholangitis. Am J Gastroenterol. 95:204–207. 2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Maroni L, Pierantonelli I, Banales JM,
Benedetti A and Marzioni M: The significance of genetics for
cholangiocarcinoma development. Ann Transl Med.
1(28)2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sheffield BS, Tessier-Cloutier B, Li-Chang
H, Shen Y, Pleasance E, Kasaian K, Li Y, Jones SJ, Lim HJ, Renouf
DJ, et al: Personalized oncogenomics in the management of
gastrointestinal carcinomas-early experiences from a pilot study.
Curr Oncol. 23:e571–e575. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ashkenazi R, Gentry SN and Jackson TL:
Pathways to tumorigenesis-modeling mutation acquisition in stem
cells and their progeny. Neoplasia. 10:1170–1182. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Berretta M, Cavaliere C, Alessandrini L,
Stanzione B, Facchini G, Balestreri L, Perin T and Canzonieri V:
Serum and tissue markers in hepatocellular carcinoma and
cholangiocarcinoma: Clinical and prognostic implications.
Oncotarget. 8:14192–14220. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhou J, Liu Z, Yang S and Li X:
Identification of microRNAs as biomarkers for cholangiocarcinoma
detection: A diagnostic meta-analysis. Clin Res Hepatol
Gastroenterol. 41:156–162. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rashid A: Cellular and molecular biology
of biliary tract cancers. Surg Oncol Clin N Am. 11:995–1009.
2002.PubMed/NCBI
|
|
20
|
Lee S, Kim WH, Jung HY, Yang MH and Kang
GH: Aberrant CpG island methylation of multiple genes in
intrahepatic cholangiocarcinoma. Am J Pathol. 161:1015–1022.
2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Goeppert B, Konermann C, Schmidt CR,
Bogatyrova O, Geiselhart L, Ernst C, Gu L, Becker N, Zucknick M,
Mehrabi A, et al: Global alterations of DNA methylation in
cholangiocarcinoma target the Wnt signaling pathway. Hepatology.
59:544–554. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kang YK, Kim WH, Lee HW, Lee HK and Kim
YI: Mutation of p53 and K-ras, and loss of heterozygosity of APC in
intrahepatic cholangiocarcinoma. Lab Invest. 79:477–483.
1999.PubMed/NCBI
|
|
25
|
Sturm PD, Baas IO, Clement MJ, Nakeeb A,
Johan G, Offerhaus A, Hruban RH and Pitt HA: Alterations of the p53
tumor-suppressor gene and K-ras oncogene in perihilar
cholangiocarcinomas from a high-incidence area. Int J Cancer.
78:695–698. 1998.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kiba T, Tsuda H, Pairojkul C, Inoue S,
Sugimura T and Hirohashi S: Mutations of the p53 tumor suppressor
gene and the ras gene family in intrahepatic cholangiocellular
carcinomas in Japan and Thailand. Mol Carcinog. 8:312–318.
1993.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wattanasirichaigoon S, Tasanakhajorn U and
Jesadapatarakul S: The incidence of K-ras codon 12 mutations in
cholangiocarcinoma detected by polymerase chain reaction technique.
J Med Assoc Thai. 81:316–323. 1998.PubMed/NCBI
|
|
28
|
Ahrendt SA, Eisenberger CF, Yip L, Rashid
A, Chow JT, Pitt HA and Sidransky D: Chromosome 9p21 loss and p16
inactivation in primary sclerosing cholangitis-associated
cholangiocarcinoma. J Surg Res. 84:88–93. 1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tannapfel A, Benicke M, Katalinic A,
Uhlmann D, Köckerling F, Hauss J and Wittekind C: Frequency of
p16(INK4A) alterations and K-ras mutations in intrahepatic
cholangiocarcinoma of the liver. Gut. 47:721–727. 2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sugimachi K, Taguchi K, Aishima S, Tanaka
S, Shimada M, Kajiyama K, Sugimachi K and Tsuneyoshi M: Altered
expression of beta-catenin without genetic mutation in intrahepatic
cholangiocarcinoma. Mod Pathol. 14:900–905. 2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang B, House MG, Guo M, Herman JG and
Clark DP: Promoter methylation profiles of tumor suppressor genes
in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol.
18:412–420. 2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ueki T, Hsing AW, Gao YT, Wang BS, Shen
MC, Cheng J, Deng J, Fraumeni JF Jr and Rashid A: Alterations of
p16 and prognosis in biliary tract cancers from a population-based
study in China. Clin Cancer Res. 10:1717–1725. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tozawa T, Tamura G, Honda T, Nawata S,
Kimura W, Makino N, Kawata S, Sugai T, Suto T and Motoyama T:
Promoter hypermethylation of DAP-kinase is associated with poor
survival in primary biliary tract carcinoma patients. Cancer Sci.
95:736–740. 2004.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tannapfel A, Sommerer F, Benicke M,
Weinans L, Katalinic A, Geissler F, Uhlmann D, Hauss J and
Wittekind C: Genetic and epigenetic alterations of the INK4a-ARF
pathway in cholangiocarcinoma. J Pathol. 197:624–631.
2002.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sasaki M, Yamaguchi J, Itatsu K, Ikeda H
and Nakanuma Y: Over-expression of polycomb group protein EZH2
relates to decreased expression of p16 INK4a in
cholangiocarcinogenesis in hepatolithiasis. J Pathol. 215:175–183.
2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chinnasri P, Pairojkul C, Jearanaikoon P,
Sripa B, Bhudhisawasdi V, Tantimavanich S and Limpaiboon T:
Preferentially different mechanisms of inactivation of 9p21 gene
cluster in liver fluke-related cholangiocarcinoma. Hum Pathol.
40:817–826. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hong SM, Choi J, Ryu K, Ro JY and Yu E:
Promoter hypermethylation of the p16 gene and loss of its protein
expression is correlated with tumor progression in extrahepatic
bile duct carcinomas. Arch Pathol Lab Med. 130:33–38.
2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wong N, Li L, Tsang K, Lai PB, To KF and
Johnson PJ: Frequent loss of chromosome 3p and hypermethylation of
RASSF1A in cholangiocarcinoma. J Hepatol. 37:633–639.
2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Abraham SC, Lee JH, Boitnott JK, Argani P,
Furth EE and Wu TT: Microsatellite instability in intraductal
papillary neoplasms of the biliary tract. Mod Pathol. 15:1309–1317.
2002.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Limpaiboon T, Khaenam P, Chinnasri P,
Soonklang M, Jearanaikoon P, Sripa B, Pairojkul C and Bhudhisawasdi
V: Promoter hypermethylation is a major event of hMLH1 gene
inactivation in liver fluke related cholangiocarcinoma. Cancer
Lett. 217:213–219. 2005.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Foja S, Goldberg M, Schagdarsurengin U,
Dammann R, Tannapfel A and Ballhausen WG: Promoter methylation and
loss of coding exons of the fragile histidine triad (FHIT) gene in
intrahepatic cholangiocarcinomas. Liver Int. 25:1202–1208.
2005.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liu XF, Zhu SG, Zhang H, Xu Z, Su HL, Li
SJ and Zhou XT: The methylation status of the TMS1/ASC gene in
cholangiocarcinoma and its clinical significance. Hepatobiliary
Pancreat Dis Int. 5:449–453. 2006.PubMed/NCBI
|
|
44
|
Koga Y, Kitajima Y, Miyoshi A, Sato K,
Kitahara K, Soejima H and Miyazaki K: Tumor progression through
epigenetic gene silencing of O(6)-methylguanine-DNA
methyltransferase in human biliary tract cancers. Ann Surg Oncol.
12:354–363. 2005.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tischoff I, Markwarth A, Witzigmann H,
Uhlmann D, Hauss J, Mirmohammadsadegh A, Wittekind C, Hengge UR and
Tannapfel A: Allele loss and epigenetic inactivation of 3p21.3 in
malignant liver tumors. Int J Cancer. 115:684–689. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sriraksa R, Zeller C, El-Bahrawy MA, Dai
W, Daduang J, Jearanaikoon P, Chau-In S, Brown R and Limpaiboon T:
CpG-island methylation study of liver fluke-related
cholangiocarcinoma. Br J Cancer. 104:1313–1318. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Khaenam P, Jearanaikoon P, Pairojkul C,
Bhudhisawasdi V and Limpaiboon T: Genetic and epigenetic
alterations of RIZ1 and the correlation to clinicopathological
parameters in liver fluke-related cholangiocarcinoma. Exp Ther Med.
1:385–390. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Khaenam P, Niibori A, Okada S,
Jearanaikoon P, Araki N and Limpaiboon T: Contribution of RIZ1 to
regulation of proliferation and migration of a liver fluke-related
cholangiocarcinoma cell. Asian Pac J Cancer Prev. 13:4007–4011.
2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Nakanuma Y, Uchida T, Sato Y and Uesaka K:
An S100P-positive biliary epithelial field is a preinvasive
intraepithelial neoplasm in nodular-sclerosing cholangiocarcinoma.
Hum Pathol. 60:46–57. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Khorasanizadeh S: The nucleosome: From
genomic organization to genomic regulation. Cell. 116:259–272.
2004.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Berger SL: Histone modifications in
transcriptional regulation. Curr Opin Genet Dev. 12:142–148.
2002.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Grant PA: A tale of histone modifications.
Genome Biol. 2(Reviews0003)2001.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Taby R and Issa JP: Cancer epigenetics. CA
Cancer J Clin. 60:376–392. 2010.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Shukla V, Vaissiere T and Herceg Z:
Histone acetylation and chromatin signature in stem cell identity
and cancer. Mutat Res. 637:1–15. 2008.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Cheung P and Lau P: Epigenetic regulation
by histone methylation and histone variants. Mol Endocrinol.
19:563–573. 2005.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Morine Y, Shimada M, Iwahashi S,
Utsunomiya T, Imura S, Ikemoto T, Mori H, Hanaoka J and Miyake H:
Role of histone deacetylase expression in intrahepatic
cholangiocarcinoma. Surgery. 151:412–419. 2012.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Baradari V, Höpfner M, Huether A, Schuppan
D and Scherübl H: Histone deacetylase inhibitor MS-275 alone or
combined with bortezomib or sorafenib exhibits strong
antiproliferative action in human cholangiocarcinoma cells. World J
Gastroenterol. 13:4458–4466. 2007.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Xu LN, Wang X and Zou SQ: Effect of
histone deacetylase inhibitor on proliferation of biliary tract
cancer cell lines. World J Gastroenterol. 14:2578–2581.
2008.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Bluethner T, Niederhagen M, Caca K, Serr
F, Witzigmann H, Moebius C, Mossner J and Wiedmann M: Inhibition of
histone deacetylase for the treatment of biliary tract cancer: A
new effective pharmacological approach. World J Gastroenterol.
13:4761–4770. 2007.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3(e85)2005.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Chuang JC and Jones PA: Epigenetics and
microRNAs. Pediatr Res. 61:24R–29R. 2007.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Ehrlich L, Hall C, Venter J, Dostal D,
Bernuzzi F, Invernizzi P, Meng F, Trzeciakowski JP, Zhou T,
Standeford H, et al: miR-24 inhibition increases menin expression
and decreases cholangiocarcinoma proliferation. Am J Pathol.
187:570–580. 2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Stutes M, Tran S and DeMorrow S: Genetic
and epigenetic changes associated with cholangiocarcinoma: From DNA
methylation to microRNAs. World J Gastroenterol. 13:6465–6469.
2007.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Zhang J, Han C and Wu T: MicroRNA-26a
promotes cholangiocarcinoma growth by activating β-catenin.
Gastroenterology. 143:246–256, e8. 2012.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Goeppert B, Ernst C, Baer C, Roessler S,
Renner M, Mehrabi A, Hafezi M, Pathil A, Warth A, Stenzinger A, et
al: Cadherin-6 is a putative tumor suppressor and target of
epigenetically dysregulated miR-429 in cholangiocarcinoma.
Epigenetics. 11:780–790. 2016.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Karakatsanis A, Papaconstantinou I,
Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of
microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,
miR-221, miR-222, and miR-223 in patients with hepatocellular
carcinoma or intrahepatic cholangiocarcinoma and its prognostic
significance. Mol Carcinog. 52:297–303. 2013.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Braconi C, Huang N and Patel T:
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor
suppressor gene expression by interleukin-6 in human malignant
cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zeng B, Li Z, Chen R, Guo N, Zhou J, Zhou
Q, Lin Q, Cheng D, Liao Q, Zheng L and Gong Y: Epigenetic
regulation of miR-124 by hepatitis C virus core protein promotes
migration and invasion of intrahepatic cholangiocarcinoma cells by
targeting SMYD3. FEBS Lett. 586:3271–3278. 2012.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Li B, Han Q, Zhu Y, Yu Y, Wang J and Jiang
X: Down-regulation of miR-214 contributes to intrahepatic
cholangiocarcinoma metastasis by targeting Twist. FEBS J.
279:2393–2398. 2012.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Scott GK, Mattie MD, Berger CE, Benz SC
and Benz CC: Rapid alteration of microRNA levels by histone
deacetylase inhibition. Cancer Res. 66:1277–1281. 2006.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Valeri N, Vannini I, Fanini F, Calore F,
Adair B and Fabbri M: Epigenetics, miRNAs, and human cancer: A new
chapter in human gene regulation. Mamm Genome. 20:573–580.
2009.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Han L, Witmer PD, Casey E, Valle D and
Sukumar S: DNA methylation regulates MicroRNA expression. Cancer
Biol Ther. 6:1284–1288. 2007.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Wang WT, Ye H, Wei PP, Han BW, He B, Chen
ZH and Chen YQ: LncRNAs H19 and HULC, activated by oxidative
stress, promote cell migration and invasion in cholangiocarcinoma
through a ceRNA manner. J Hematol Oncol. 9(117)2016.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Yang W, Li Y, Song X, Xu J and Xie J:
Genome-wide analysis of long noncoding RNA and mRNA co-expression
profile in intrahepatic cholangiocarcinoma tissue by RNA
sequencing. Oncotarget. 8:26591–26599. 2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Wang J, Xie H, Ling Q, Lu D, Lv Z, Zhuang
R, Liu Z, Wei X, Zhou L, Xu X and Zheng S: Coding-noncoding gene
expression in intrahepatic cholangiocarcinoma. Transl Res.
168:107–121. 2016.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Jiang XM, Li ZL, Li JL, Zheng WY, Li XH,
Cui YF and Sun DJ: LncRNA CCAT1 as the unfavorable prognostic
biomarker for cholangiocarcinoma. Eur Rev Med Pharmacol Sci.
21:1242–1247. 2017.PubMed/NCBI
|
|
80
|
Shi X, Zhang H, Wang M, Xu X, Zhao Y, He
R, Zhang M, Zhou M, Li X, Peng F, et al: LncRNA AFAP1-AS1 promotes
growth and metastasis of cholangiocarcinoma cells. Oncotarget.
8:58394–58404. 2017.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Wan M, Zhang FM, Li ZL, Kang PC, Jiang PM,
Wang YM, Wang ZD, Zhong XY, Li CL, Wang H, et al: Identifying
survival-associated ceRNA clusters in cholangiocarcinoma. Oncol
Rep. 36:1542–1550. 2016.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Tan X, Huang Z and Li X: Long non-coding
RNA MALAT1 interacted with miR-204 to modulates human hilar
cholangiocarcinoma proliferation, migration and invasion by
targeting CXCR4. J Cell Biochem. 118:3643–3653. 2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Ma SL, Li AJ, Hu ZY, Shang FS and Wu MC:
Coexpression of the carbamoylphosphate synthase 1 gene and its long
noncoding RNA correlates with poor prognosis of patients with
intrahepatic cholangiocarcinoma. Mol Med Rep. 12:7915–7926.
2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Parasramka M, Yan IK, Wang X, Nguyen P,
Matsuda A, Maji S, Foye C, Asmann Y and Patel T: BAP1 dependent
expression of long non-coding RNA NEAT-1 contributes to sensitivity
to gemcitabine in cholangiocarcinoma. Mol Cancer.
16(22)2017.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Davaadorj M, Saito Y, Morine Y, Ikemoto T,
Imura S, Takasu C, Yamada S, Hiroki T, Yoshikawa M and Shimada M:
Loss of secreted frizzled-related protein-1 expression is
associated with poor prognosis in intrahepatic cholangiocarcinoma.
Eur J Surg Oncol. 43:344–350. 2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Davaadorj M, Imura S, Saito YU, Morine Y,
Ikemoto T, Yamada S, Takasu C, Hiroki T, Yoshikawa M and Shimada M:
Loss of SFRP1 expression is associated with poor prognosis in
hepatocellular carcinoma. Anticancer Res. 36:659–664.
2016.PubMed/NCBI
|
|
87
|
Khoontawad J, Pairojkul C, Rucksaken R,
Pinlaor P, Wongkham C, Yongvanit P, Pugkhem A, Jones A, Plieskatt
J, Potriquet J, et al: Differential protein expression marks the
transition from infection with Opisthorchis viverrini to
cholangiocarcinoma. Mol Cell Proteomics. 16:911–923.
2017.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Sempoux C, Jibara G, Ward SC, Fan C, Qin
L, Roayaie S, Fiel MI, Schwartz M and Thung SN: Intrahepatic
cholangiocarcinoma: New insights in pathology. Semin Liver Dis.
31:49–60. 2011.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Lok T, Chen L, Lin F and Wang HL:
Immunohistochemical distinction between intrahepatic
cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum
Pathol. 45:394–400. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Kanzawa M, Sanuki T, Onodera M, Fujikura
K, Itoh T and Zen Y: Double immunostaining for maspin and p53 on
cell blocks increases the diagnostic value of biliary brushing
cytology. Pathol Int. 67:91–98. 2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Zen Y, Britton D, Mitra V, Pike I, Sarker
D, Itoh T, Heaton N and Quaglia A: Tubulin β-III: A novel
immunohistochemical marker for intrahepatic peripheral
cholangiocarcinoma. Histopathology. 65:784–792. 2014.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Mustafa MZ, Nguyen VH, Le Naour F, De
Martin E, Beleoken E, Guettier C, Johanet C, Samuel D,
Duclos-Vallee JC and Ballot E: Autoantibody signatures defined by
serological proteome analysis in sera from patients with
cholangiocarcinoma. J Transl Med. 14(17)2016.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Rucksaken R, Pairojkul C, Pinlaor P,
Khuntikeo N, Roytrakul S, Selmi C and Pinlaor S: Plasma
autoantibodies against heat shock protein 70, enolase 1 and
ribonuclease/angiogenin inhibitor 1 as potential biomarkers for
cholangiocarcinoma. PLoS One. 9(e103259)2014.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Le Faouder J, Laouirem S, Alexandrov T,
Ben-Harzallah S, Léger T, Albuquerque M, Bedossa P and Paradis V:
Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by
MALDI imaging mass spectrometry. Proteomics. 14:965–972.
2014.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Maeda S, Morikawa T, Takadate T, Suzuki T,
Minowa T, Hanagata N, Onogawa T, Motoi F, Nishimura T and Unno M:
Mass spectrometry-based proteomic analysis of formalin-fixed
paraffin-embedded extrahepatic cholangiocarcinoma. J Hepatobiliary
Pancreat Sci. 22:683–691. 2015.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Stephenson B, Shimwell N, Humphreys E,
Ward D, Adams D, Martin A and Afford S: Quantitative assessment of
the cell surface proteome to identify novel therapeutic targets in
cholangiocarcinoma. Lancet. ١ (Suppl 385)(S94)2015.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Janvilisri T, Leelawat K, Roytrakul S,
Paemanee A and Tohtong R: Novel serum biomarkers to differentiate
cholangiocarcinoma from benign biliary tract diseases using a
proteomic approach. Dis Markers. 2015(105358)2015.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Adisakwattana P, Suwandittakul N, Petmitr
S, Wongkham S, Sangvanich P and Reamtong O: ALCAM is a novel
cytoplasmic membrane protein in TNF-α stimulated invasive
cholangiocarcinoma cells. Asian Pac J Cancer Prev. 16:3849–3856.
2015.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Wasuworawong K, Roytrakul S, Paemanee A,
Jindapornprasert K and Komyod W: Comparative proteomic analysis of
human cholangiocarcinoma cell lines: S100A2 as a potential
candidate protein inducer of invasion. Dis Markers.
2015(629367)2015.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Haonon O, Rucksaken R, Pinlaor P,
Pairojkul C, Chamgramol Y, Intuyod K, Onsurathum S, Khuntikeo N and
Pinlaor S: Upregulation of 14-3-3 eta in chronic liver fluke
infection is a potential diagnostic marker of cholangiocarcinoma.
Proteomics Clin Appl. 10:248–256. 2016.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Seol MA, Chu IS, Lee MJ, Yu GR, Cui XD,
Cho BH, Ahn EK, Leem SH, Kim IH and Kim DG: Genome-wide expression
patterns associated with oncogenesis and sarcomatous
transdifferentation of cholangiocarcinoma. BMC Cancer.
11(78)2011.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Yang XW, Li L, Hou GJ, Yan XZ, Xu QG, Chen
L, Zhang BH and Shen F: STAT3 overexpression promotes metastasis in
intrahepatic cholangiocarcinoma and correlates negatively with
surgical outcome. Oncotarget. 8:7710–7721. 2017.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Braconi C, Swenson E, Kogure T, Huang N
and Patel T: Targeting the IL-6 dependent phenotype can identify
novel therapies for cholangiocarcinoma. PLoS One.
5(e15195)2010.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Beisler JA: Isolation, characterization,
and properties of a labile hydrolysis product of the antitumor
nucleoside, 5-azacytidine. J Med Chem. 21:204–208. 1978.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Cheng JC, Weisenberger DJ, Gonzales FA,
Liang G, Xu GL, Hu YG, Marquez VE and Jones PA: Continuous
zebularine treatment effectively sustains demethylation in human
bladder cancer cells. Mol Cell Biol. 24:1270–1278. 2004.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Marquez VE, Barchi JJ Jr, Kelley JA, Rao
KV, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB and Jones PA:
Zebularine: A unique molecule for an epigenetically based strategy
in cancer chemotherapy. The magic of its chemistry and biology.
Nucleosides Nucleotides Nucleic Acids. 24:305–318. 2005.PubMed/NCBI
|
|
108
|
Nakamura K, Nakabayashi K, Htet Aung K,
Aizawa K, Hori N, Yamauchi J, Hata K and Tanoue A: DNA
methyltransferase inhibitor zebularine induces human
cholangiocarcinoma cell death through alteration of DNA methylation
status. PLoS One. 10(e0120545)2015.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Kelly WK and Marks PA: Drug insight:
Histone deacetylase inhibitors-development of the new targeted
anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract
Oncol. 2:150–157. 2005.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Sriraksa R and Limpaiboon T: Histone
deacetylases and their inhibitors as potential therapeutic drugs
for cholangiocarcinoma-cell line findings. Asian Pac J Cancer Prev.
14:2503–2508. 2013.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Nakagawa S, Sakamoto Y, Okabe H, Hayashi
H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima
K, et al: Epigenetic therapy with the histone methyltransferase
EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of
cholangiocarcinoma cells. Oncol Rep. 31:983–988. 2014.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Gores GJ: Early detection and treatment of
cholangiocarcinoma. Liver Transpl. 6 (6 Suppl 2):S30–S34.
2000.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Nakaoka T, Saito Y and Saito H: Aberrant
DNA methylation as a biomarker and a therapeutic target of
cholangiocarcinoma. Int J Mol Sci. 18(E1111)2017.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Jusakul A, Cutcutache I, Yong CH, Lim JQ,
Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, et
al: Whole-genome and epigenomic landscapes of etiologically
distinct subtypes of cholangiocarcinoma. Cancer Discov.
7:1116–1135. 2017.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Ettel M, Eze O and Xu R: Clinical and
biological significance of precursor lesions of intrahepatic
cholangiocarcinoma. World J Hepatol. 7:2563–2570. 2015.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Fujimoto A, Furuta M, Shiraishi Y, Gotoh
K, Kawakami Y, Arihiro K, Nakamura T, Ueno M, Ariizumi S, Nguyen
HH, et al: Whole-genome mutational landscape of liver cancers
displaying biliary phenotype reveals hepatitis impact and molecular
diversity. Nat Commun. 6(6120)2015.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Komuta M, Govaere O, Vandecaveye V, Akiba
J, Van Steenbergen W, Verslype C, Laleman W, Pirenne J, Aerts R,
Yano H, et al: Histological diversity in cholangiocellular
carcinoma reflects the different cholangiocyte phenotypes.
Hepatology. 55:1876–1888. 2012.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013.PubMed/NCBI View Article : Google Scholar
|
